補體成分5(C5)活性蛋白
Active Complement Component 5 (C5)
CPAMD4; C5a anaphylatoxin; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
- 編號UAPB969Hu02
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點6.4
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 780 ¥ 1950 ¥ 3900 ¥ 11700 ¥ 29250
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
活性實驗
Complement Component 5 (C5), which forms part of the later stages of the complement pathway, is cleaved?into?C5a and C5b. C5a is a chemotactic agent for neutrophils, while?C5b?forms?part?of?the?complement?membrane?attack?complex. Coagulation Factor II (F2) has been identified as an interactor of C5, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human C5 and recombinant mouse F2. Briefly, C5 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to F2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-C5 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human C5 and recombinant mouse F2 was shown in Figure 1, the EC50?for this effect is 0.22 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPB969Hu01 | 補體成分5(C5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPB969Hu02 | 補體成分5(C5)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPB969Hu02 | 補體成分5(C5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB969Hu01 | 補體成分5(C5)多克隆抗體 | WB; IHC |
| UPAB969Hu02 | 補體成分5(C5)多克隆抗體 | WB; IHC; ICC; IP. |
| ULAB969Hu71 | 補體成分5(C5)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| UMAB969Hu22 | 補體成分5(C5)單克隆抗體 | WB |
| UMAB969Hu21 | 補體成分5(C5)單克隆抗體 | WB |
| USEB969Hu | 補體成分5(C5)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB969Hu | 補體成分5(C5)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Journal of Clinical Immunology | Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease. [PubMed: 22941511] |
| Journal of Neuroimmunology | Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis [Pubmed:27235358] |
| Cancer Letters | Complement C5a/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expression [pubmed:29031586] |
| Proteomics?Clinical?Applications | iTRAQ‐Based Proteomic Analysis Reveals Protein Profile in Plasma from Children with Autism [Pubmed:29274201] |
| American journal of physiology. Endocrinology and metabolism | Impaired insulin signaling in the B10.D2-Hc H2 H2-T18/oSnJ mouse model of complement factor 5 (C5) deficiency [Pubmed: 31084499] |
| Proteomics Clinical Applications | Comparative proteomics analysis of serum proteins in gestational diabetes during early and middle stages of pregnancy [Pubmed: 31162828] |
| Aging | C5aR deficiency attenuates the breast cancer development via the p38/p21 axis [Pubmed: 32669478] |
